Pathology

Pediatrics

Disease

Diplopia

Biology

Ophthalmology

Surgery

Intensive care medicine

Paleontology

Dermatology

Exophthalmos

Graves' ophthalmopathy

Optic neuropathy

Graves' disease

Extraocular muscles

Parkinson's disease

Context (archaeology)

Optic nerve

Disease management

Medicine

Indian Journal of Ophthalmology

Thyroid eye disease (TED) is a rare disease that can lead to decreased quality of life, permanent disfigurement, and vision loss. Clinically, TED presents with exophthalmos, periorbital edema, extraocular muscle dysfunction, and eyelid retraction, and can lead to vision-threatening complications such as exposure to keratopathy and dysthyroid optic neuropathy (DON). Over the last several years, significant advancements have been made in the understanding of its pathophysiology as well as optimal management. Ethnic variations in the prevalence, clinical presentation, and risk of vision-threatening complications of TED are summarized, and risk factors associated with TED are discussed. Additionally, significant advances have been made in the management of TED. The management of TED traditionally included anti-inflammatory medications, orbital radiation therapy, orbital surgical decompression, and biologic therapies. Most recently, targeted therapies such as teprotumumab, an insulin-like growth factor-1 receptor antagonist, have been studied in the context of TED, with promising initial data. In this review, updates in the understanding and management of TED are presented with a focus on the international variations in presentation and management.

Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management